

James L Abbruzzese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10500649/publications.pdf>

Version: 2024-02-01

76
papers

15,198
citations

41627

51
h-index

87275

74
g-index

76
all docs

76
docs citations

76
times ranked

19393
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2723.	1.7	6
2	Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity. <i>Cancers</i> , 2021, 13, 778.	1.7	9
3	Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis. <i>Cell Death and Disease</i> , 2021, 12, 189.	2.7	6
4	Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS. <i>Cell Communication and Signaling</i> , 2019, 17, 19.	2.7	19
5	Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells. <i>Methods in Molecular Biology</i> , 2019, 1882, 207-219.	0.4	3
6	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw266.	3.0	116
7	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	0.9	124
8	Development of a Novel c-MET-Based CTC Detection Platform. <i>Molecular Cancer Research</i> , 2016, 14, 539-547.	1.5	37
9	Molecular Pathogenesis of Pancreatic Adenocarcinoma. , 2015, , 515-522.e2.		0
10	Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. <i>Physical Biology</i> , 2014, 11, 065002.	0.8	32
11	Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 16-25.	0.9	172
12	Transport properties of pancreatic cancer describe gemcitabine delivery and response. <i>Journal of Clinical Investigation</i> , 2014, 124, 1525-1536.	3.9	164
13	Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. <i>Human Pathology</i> , 2013, 44, 1024-1030.	1.1	22
14	Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 2197-2203.	0.7	61
15	The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 500-508.	0.7	61
16	Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. <i>Histopathology</i> , 2013, 63, 841-851.	1.6	34
17	Genetic variation in the <i>PNPLA3</i> gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. <i>Molecular Carcinogenesis</i> , 2013, 52, 139-147.	1.3	68
18	Perineural and Intra-neural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 409-417.	2.1	158

#	ARTICLE	IF	CITATIONS
19	Tumor Invasion of Muscular Vessels Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma Who Have Received Neoadjuvant Therapy and Pancreaticoduodenectomy. <i>American Journal of Surgical Pathology</i> , 2012, 36, 552-559.	2.1	53
20	Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. <i>Annals of Diagnostic Pathology</i> , 2012, 16, 29-37.	0.6	110
21	Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2012, 118, 3182-3190.	2.0	216
22	Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. <i>Cancer</i> , 2012, 118, 3801-3811.	2.0	61
23	Multimodality Therapy Offers a Chance for Cure in Patients with Pancreatic Adenocarcinoma Deemed Unresectable at First Operative Exploration. <i>Journal of the American College of Surgeons</i> , 2012, 215, 41-51.	0.2	30
24	Posttherapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. <i>Cancer</i> , 2012, 118, 268-277.	2.0	81
25	ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. <i>PLoS ONE</i> , 2011, 6, e20636.	1.1	241
26	Association of multiple drug resistance gene polymorphisms with pancreatic cancer outcome. <i>Cancer</i> , 2011, 117, 744-751.	2.0	60
27	DNA Mismatch Repair Gene Polymorphisms Affect Survival in Pancreatic Cancer. <i>Oncologist</i> , 2011, 16, 61-70.	1.9	247
28	Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation. <i>Annals of Surgical Oncology</i> , 2010, 17, 1794-1801.	0.7	129
29	Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 1938-1946.	2.0	283
30	Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity. <i>Clinical Cancer Research</i> , 2010, 16, 320-329.	3.2	92
31	Chemoprevention of Pancreatic Cancer: Ready for the Clinic?. <i>Cancer Prevention Research</i> , 2010, 3, 1375-1378.	0.7	7
32	Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. <i>Cancer Research</i> , 2009, 69, 5820-5828.	0.4	771
33	Significant Associations of Mismatch Repair Gene Polymorphisms With Clinical Outcome of Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1592-1599.	0.8	46
34	Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 836-47.	0.7	435
35	The association of family history of liver cancer with hepatocellular carcinoma: A case-control study in the United States. <i>Journal of Hepatology</i> , 2009, 50, 334-341.	1.8	73
36	Antidiabetic Therapies Affect Risk of Pancreatic Cancer. <i>Gastroenterology</i> , 2009, 137, 482-488.	0.6	536

#	ARTICLE	IF	CITATIONS
37	Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case-control study. <i>International Journal of Cancer</i> , 2008, 123, 1883-1891.	2.3	73
38	Development of an Integrated Biospecimen Bank and Multidisciplinary Clinical Database For Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 1356-1366.	0.7	58
39	Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 4491-4499.	3.2	1,158
40	Association Between Hepatitis B Virus and Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4557-4562.	0.8	159
41	LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 829-840.	1.9	285
42	Single-Nucleotide Polymorphisms of DNA Damage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2042-2048.	3.2	53
43	Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head. <i>Journal of Clinical Oncology</i> , 2008, 26, 3496-3502.	0.8	684
44	Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head. <i>Journal of Clinical Oncology</i> , 2008, 26, 3487-3495.	0.8	441
45	Molecular Pathogenesis of Pancreatic Adenocarcinoma. , 2008, , 455-461.		0
46	Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of <i>Twist</i> Gene Expression. <i>Cancer Research</i> , 2007, 67, 9066-9076.	0.4	605
47	Risk Factors for Pancreatic Cancer: Case-Control Study. <i>American Journal of Gastroenterology</i> , 2007, 102, 2696-2707.	0.2	280
48	Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution. <i>Carcinogenesis</i> , 2007, 28, 1794-1799.	1.3	16
49	Targeted Expression of BikDD Eradicates Pancreatic Tumors in Noninvasive Imaging Models. <i>Cancer Cell</i> , 2007, 12, 52-65.	7.7	71
50	Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation. <i>Journal of Pain and Symptom Management</i> , 2007, 34, 244-252.	0.6	48
51	Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy. <i>Annals of Surgical Oncology</i> , 2006, 13, 1035-1046.	0.7	803
52	Tolfenamic Acid and Pancreatic Cancer Growth, Angiogenesis, and Sp Protein Degradation. <i>Journal of the National Cancer Institute</i> , 2006, 98, 855-868.	3.0	165
53	Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients. <i>International Journal of Cancer</i> , 2006, 119, 1455-1461.	2.3	18
54	Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1145-1151.	0.8	203

#	ARTICLE	IF	CITATIONS
55	Simultaneous Inhibition of EGFR, VEGFR, and Platelet-Derived Growth Factor Receptor Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse Model. <i>Cancer Research</i> , 2005, 65, 10371-10380.	0.4	96
56	Induction of Apoptosis in Tumor-Associated Endothelial Cells and Therapy of Orthotopic Human Pancreatic Carcinoma in Nude Mice. <i>Neoplasia</i> , 2005, 7, 696-704.	2.3	29
57	The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF- κ B and c-Myc in pancreatic cancer cells. <i>Oncogene</i> , 2004, 23, 8571-8580.	2.6	283
58	The convergence of cancer prevention and therapy in early-phase clinical drug development. <i>Cancer Cell</i> , 2004, 6, 321-326.	7.7	50
59	Novel therapies for pancreatic adenocarcinoma. <i>Current Gastroenterology Reports</i> , 2004, 6, 119-125.	1.1	14
60	Novel therapies for pancreatic adenocarcinoma. <i>Current Oncology Reports</i> , 2004, 6, 199-206.	1.8	20
61	Cytokines in pancreatic carcinoma. <i>Cancer</i> , 2004, 101, 2727-2736.	2.0	273
62	NF- κ B activity blockade impairs the angiogenic potential of human pancreatic cancer cells. <i>International Journal of Cancer</i> , 2004, 108, 181-188.	2.3	108
63	Pancreatic cancer. <i>Lancet, The</i> , 2004, 363, 1049-1057.	6.3	1,761
64	Experimental Animal Models of Pancreatic Carcinogenesis and Metastasis. <i>International Journal of Gastrointestinal Cancer</i> , 2003, 33, 43-60.	0.4	21
65	Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. <i>Oncogene</i> , 2003, 22, 319-329.	2.6	510
66	A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. <i>Clinical Cancer Research</i> , 2003, 9, 555-61.	3.2	390
67	Preoperative Paclitaxel and Concurrent Rapid-Fractionation Radiation for Resectable Pancreatic Adenocarcinoma: Toxicities, Histologic Response Rates, and Event-Free Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 2537-2544.	0.8	180
68	DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2002, 513, 37-48.	0.9	77
69	Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. <i>Hepatology</i> , 2002, 36, 1206-1213.	3.6	667
70	Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration. <i>Annals of Surgical Oncology</i> , 2001, 8, 123-132.	0.7	326
71	A Novel, Clinically Relevant Animal Model of Metastatic Pancreatic Adenocarcinoma Biology and Therapy. <i>International Journal of Gastrointestinal Cancer</i> , 2001, 29, 37-46.	0.4	30
72	Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. <i>Oncogene</i> , 2001, 20, 3751-3756.	2.6	219

#	ARTICLE	IF	CITATIONS
73	Combining gemcitabine with radiation in pancreatic cancer: Understanding important variables influencing the therapeutic index. <i>Seminars in Oncology</i> , 2001, 28, 25-33.	0.8	41
74	Preoperative Chemoradiation for Patients With Pancreatic Cancer: Toxicity of Endobiliary Stents. <i>Journal of Clinical Oncology</i> , 2000, 18, 860-860.	0.8	75
75	The Need for Standardized Pathologic Staging of Pancreaticoduodenectomy Specimens. <i>Pancreas</i> , 1996, 12, 373-380.	0.5	109
76	Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. <i>American Journal of Surgery</i> , 1994, 167, 104-113.	0.9	236